Shah Capital, Novavax’s second-largest shareholder, announced on Friday that it will no longer seek to influence control or strategic direction at the vaccine maker following its restructuring into a dedicated family office.
📌 Key Filings & Stake Breakdown:
• Activist Role Exit: Shah Capital filed with the U.S. SEC to voluntarily withdraw its registration as an investment adviser, transitioning management into the newly formed Himanshu Shah Family Office LLC.
• 10.66 Million Total Shares (6.46% Stake): Founder & CIO Himanshu Shah retains beneficial ownership of 10.66 million shares, representing a 6.46% stake in Novavax (NVAX).
• 2.87 Million Share Sale: Shah Capital Fund LLC disclosed the sale of 2.87 million shares on October 5 at an average price of $11.35 per share (~$32.5 million value).
💡 Market Takeaway: The shift marks an end to active proxy pressure from one of Novavax’s largest institutional backers, providing management with operational stability as the investor transitions to passive family wealth management.